Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.

@article{Jabbour2011PredictiveFF,
  title={Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.},
  author={Elias J Jabbour and Hagop M Kantarjian and Susan M O'Brien and Jenny Shan and Guillermo Garc{\'i}a-Manero and William G Wierda and Farhad Ravandi and Gautam Borthakur and Mary Beth Rios and Jorge E. Cortes},
  journal={Blood},
  year={2011},
  volume={117 6},
  pages={1822-7}
}
We assessed the predictive factors for outcome and response in 123 patients with chronic myeloid leukemia in chronic phase treated with second-generation tyrosine kinase inhibitors (TKIs) after imatinib failure. Better event-free survival rates with second-generation TKI therapy were associated with a previous cytogenetic response to imatinib (P < .001) and… CONTINUE READING